Cataracts form gradually as our eyes get older, and 9 in 10 Americans develop them by the time they’re 65. The good news is that cataract surgery is one of the safest, most common, and most effective procedures performed today. At the time of cataract surgery, you have the opportunity to enhance your vision with the PanOptix® Lens.
Why Choose PanOptics?
PanOptics is the first and only trifocal lens in the United States, this lens is also available in a toric option to correct astigmatism. Delivering an outstanding range of vision, the PanOptix® Lens is the latest advancement from the AcrySof® Family of Lenses—the most implanted cataract replacement lenses worldwide. The PanOptix® Lens corrects and sharpens your vision, so you’re likely to wear glasses less often. No blurry zones means you can see without straining to focus.
- CATARACT REMOVAL Through a tiny incision, the surgeon removes your clouded lens.
- LENS INSERTION The surgeon replaces your original lens with the PanOptix® Lens.
- VISION RENEWED The PanOptix® Lens enhances your vision for clear, complete focus.
TALK TO YOUE EYE CARE PROFESSIONAL ABOUT THE PANOPTIX® LENS
FIND OUT MORE AT CATARACTSURGERY.COM
AcrySof® IQ PanOptix® Family of Trifocal IOLs IMPORTANT PRODUCT INFORMATION
CAUTION: Restricted by law to sale by or on the order of a physician.
DESCRIPTION: The AcrySof® IQ PanOptix® Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the AcrySof® IQ PanOptix® Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. There is a chance that you still may need glasses for distance, intermediate, and/or near vision. You will get the full benefit of the AcrySof® IQ PanOptix® Trifocal IOL when it is placed in both eyes. Please discuss with your eye doctor whether this is the right IOL for you.
POTENTIAL SIDE EFFECTS: Due to the design of multifocal IOLs, there are some side effects that can be associated with the AcrySof® IQ PanOptix® Trifocal IOL models. These may be worse than with a monofocal IOL, including visual disturbances such as glare, rings around lights, starbursts (rays around light sources), and reduced contrast sensitivity (decrease in ability to distinguish objects from their background, especially in dim lighting). These side effects may make it more difficult to see while driving at night or completing tasks in low lighting conditions, such as at night or in fog or in a dimly lit room, after surgery as compared to before surgery. Further, a toric IOL corrects astigmatism only when it is placed in the correct position in the eye. There is a possibility that the toric IOL could be placed incorrectly or could move within the eye. If the toric lens is not positioned correctly following surgery, the change in your astigmatism correction by the IOL, along with any necessary correction with glasses, may cause visual distortions. If the lens rotates in your eye, you may need additional surgery to reposition or replace the IOL.
ATTENTION: As with any surgical procedure, there are risks involved. Prior to surgery, ask your eye doctor to provide you with the Patient Information Brochure for the proposed AcrySof® IQ PanOptix® Trifocal IOL to be implanted. This document will further inform you of the risks and benefits associated with this IOL. Discuss any questions about possible risks and benefits with your eye doctor, as well as your medical condition and any eye disease you may have.
REFERENCES: 1. Alcon data on file. 2. Cataract. Kellogg Eye Center website. https://www.umkelloggeye.org/ conditions-treatments/cataract. Accessed April 23, 2019.
3. Facts about cataract. National Eye Institute website. https://nei.nih.gov/health/cataract/cataract_facts. Updated September 2015. Accessed March 19, 2019. 4. Groessl EJ, Liu L, Sklar M, Tally SR, Kaplan RM, Ganiats TG. Measuring the impact of cataract surgery on generic and vision-specific quality of life. Qual Life Res. 2013; 22:1404-1414 . doi: 10.1007/ s11136-012-0270-Z.